{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:07:36Z","timestamp":1789589256693,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Integrative Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.joim.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:15:15Z","timestamp":1783440915000},"page":"742-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation"],"prefix":"10.1016","volume":"24","author":[{"given":"Rong-fang","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-xian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-ang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.joim.2026.07.002_b0005","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.joim.2026.07.002_b0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.joim.2026.07.002_b0020","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.joim.2026.07.002_b0025","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/1440-1681.13643","article-title":"Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma","volume":"49","author":"Han","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.joim.2026.07.002_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116738","article-title":"Matrine induces autophagic cell death by triggering ROS\/AMPK\/mTOR axis and apoptosis in multiple myeloma","volume":"175","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.joim.2026.07.002_b0035","article-title":"Active components of traditional Chinese medicinal material for multiple myeloma: current evidence and future directions","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13046-019-1498-z","article-title":"Combination of the natural compound periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: implication in anticancer therapy","volume":"38","author":"Han","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.joim.2026.07.002_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121715","article-title":"Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT\/NF-\u03baB pathway","volume":"324","author":"Lin","year":"2023","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.joim.2026.07.002_b0050","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1080\/15548627.2023.2239042","article-title":"Periplocin suppresses the growth of colorectal cancer cells by triggering LGALS3 (galectin 3)-mediated lysophagy","volume":"19","author":"Wang","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.joim.2026.07.002_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114039","article-title":"Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells","volume":"157","author":"Bae","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.joim.2026.07.002_b0060","article-title":"Periplocin induces apoptosis of pancreatic cancer cells through autophagy via the AMPK\/mTOR pathway","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Oncol"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cam4.3611","article-title":"Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling","volume":"10","author":"Xie","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.joim.2026.07.002_b0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2147\/DDDT.S302221","article-title":"Inhibitory effects of Periplocin on lymphoma cells: a network pharmacology approach and experimental validation","volume":"15","author":"Zhao","year":"2021","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.joim.2026.07.002_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153262","article-title":"Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK\/p38\/JNK pathway","volume":"76","author":"Lohberger","year":"2020","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0080","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/cancers15051526","article-title":"Periplocin overcomes bortezomib resistance by suppressing the growth and down regulation of cell adhesion molecules in multiple myeloma","volume":"15","author":"Aziz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0085","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1038\/s41598-021-89074-x","article-title":"Periplocin and cardiac glycosides suppress the unfolded protein response","volume":"11","author":"Tokugawa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.joim.2026.07.002_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118737","article-title":"Uncovering the pharmacological mechanisms of Patchouli essential oil for treating ulcerative colitis","volume":"336","author":"Huang","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.joim.2026.07.002_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115573","article-title":"Integrating network pharmacology and transcriptomic validation to investigate the efficacy and mechanism of Mufangji decoction preventing lung cancer","volume":"298","author":"Gao","year":"2022","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.joim.2026.07.002_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104040","article-title":"Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives","volume":"187","author":"Costa","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"10.1016\/j.joim.2026.07.002_b0110","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.22.02665","article-title":"Daratumumab, bortezomib, and dexamethasone for previously treated multiple myeloma","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.joim.2026.07.002_b0115","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.joim.2026.07.002_b0120","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joim.2026.07.002_b0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.joim.2026.07.002_b0135","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/med.21972","article-title":"Histone deacetylase-based dual targeted inhibition in multiple myeloma","volume":"43","author":"Ferro","year":"2023","journal-title":"Med Res Rev"},{"key":"10.1016\/j.joim.2026.07.002_b0140","doi-asserted-by":"crossref","unstructured":"XPO1 inhibitor approved for multiple myeloma. Cancer Discov 2019; 9(9): 1150\u20131.","DOI":"10.1158\/2159-8290.CD-NB2019-085"},{"issue":"8","key":"10.1016\/j.joim.2026.07.002_b0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/tox.23981","article-title":"Study of the PI3K\/Akt\/mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231","volume":"39","author":"Liu","year":"2024","journal-title":"Environ Toxicol"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"10.1016\/j.joim.2026.07.002_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153574","article-title":"Blockage of the JAK\/STAT3 signaling pathway in multiple myeloma by leelamine","volume":"87","author":"Jung","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.joim.2026.07.002_b0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.freeradbiomed.2023.04.003","article-title":"Targeting ABCB6 with nitidine chloride inhibits PI3K\/AKT signaling pathway to promote ferroptosis in multiple myeloma","volume":"203","author":"Yin","year":"2023","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","article-title":"Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.joim.2026.07.002_b0175","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0185","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)64278-2","article-title":"Analysis of signal transducer and activator of transcription 3 (STAT3) pathway in multiple myeloma: STAT 3 activation and cyclin D1 dysregulation are mutually exclusive events","volume":"162","author":"Quintanilla-Martinez","year":"2003","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.joim.2026.07.002_b0190","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5045\/br.2017.52.4.293","article-title":"STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma","volume":"52","author":"Jung","year":"2017","journal-title":"Blood Res"},{"issue":"5","key":"10.1016\/j.joim.2026.07.002_b0195","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s13402-023-00817-6","article-title":"Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells","volume":"46","author":"Li","year":"2023","journal-title":"Cell Oncol (Dordr)"}],"container-title":["Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496426000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496426000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:00Z","timestamp":1789588560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095496426000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2095496426000865"],"URL":"https:\/\/doi.org\/10.1016\/j.joim.2026.07.002","relation":{},"ISSN":["2095-4964"],"issn-type":[{"value":"2095-4964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation","name":"articletitle","label":"Article Title"},{"value":"Journal of Integrative Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joim.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}